EyePoint Pharmaceuticals to Present at the Guggenheim Healthcare Talks 6th Annual Biotechnology ConferenceGlobeNewsWire • 01/31/24
EyePoint Pharmaceuticals Announces First Patient Dosed in Phase 2 VERONA Clinical Trial of EYP-1901 for the Treatment of Diabetic Macular EdemaGlobeNewsWire • 01/10/24
EyePoint Pharmaceuticals to Present at the 42nd Annual J.P. Morgan Healthcare ConferenceGlobeNewsWire • 12/20/23
EyePoint Pharmaceuticals (EYPT) is a Great Momentum Stock: Should You Buy?Zacks Investment Research • 12/11/23
Wall Street Analysts Believe EyePoint Pharmaceuticals (EYPT) Could Rally 77.05%: Here's is How to TradeZacks Investment Research • 12/08/23
What Makes EyePoint Pharmaceuticals (EYPT) a Good Fit for 'Trend Investing'Zacks Investment Research • 12/08/23
EyePoint announces $175 million stock offering following record surge in share priceMarket Watch • 12/04/23
EyePoint Pharmaceuticals' stock soars 362% after company announces positive data from trial of wet AMD treatmentMarket Watch • 12/04/23
EyePoint Pharmaceuticals Announces Positive Topline Data from the Phase 2 DAVIO 2 Trial of EYP-1901 in Wet AMD Achieving All Primary and Secondary EndpointsGlobeNewsWire • 12/04/23
Does EyePoint Pharmaceuticals (EYPT) Have the Potential to Rally 336.07% as Wall Street Analysts Expect?Zacks Investment Research • 11/21/23
EyePoint Pharmaceuticals, Inc. (EYPT) Q3 2023 Earnings Conference Call TranscriptSeeking Alpha • 11/01/23
EyePoint Pharmaceuticals Reports Third Quarter 2023 Financial Results and Highlights Recent Corporate DevelopmentsGlobeNewsWire • 11/01/23
EyePoint Pharmaceuticals to Host Virtual Key Opinion Leader (KOL) Event on November 9, 2023GlobeNewsWire • 10/31/23
EyePoint Pharmaceuticals Announces Presentations at Eyecelerator 2023, American Academy of Ophthalmology Annual Meeting 2023 and Guggenheim's 5th Annual Inflammation, Neurology & Immunology Conference 2023GlobeNewsWire • 10/30/23
EyePoint Pharmaceuticals to Report Third Quarter 2023 Financial Results on November 1, 2023GlobeNewsWire • 10/25/23